Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Stopped early · Phase 1/Phase 2
Conditions studied: Non Small Cell Lung Cancer
In brief
The purpose of this study was to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of nazartinib (EGF816) in combination with capmatinib (INC280) and to estimate the preliminary anti-tumor activity of nazartinib in combination with capmatinib in participants with advanced non-small cell lung cancer (NSCLC) with documented EGFR mutation.
Key facts
- Study ID
- NCT02335944
- Run by
- Novartis Pharmaceuticals
- People needed
- 177
- Starts
- 2015-01-13
- Expected to finish
- 2020-11-10
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital Mass General — Boston, Massachusetts, United States
- Novartis Investigative Site — Melbourne, Victoria, Australia
- Novartis Investigative Site — Edmonton, Alberta, Canada
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Heidelberg, Baden-Wurttemberg, Germany
- Novartis Investigative Site — Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site — Bologna, BO, Italy
- Novartis Investigative Site — Modena, MO, Italy
- Novartis Investigative Site — Perugia, PG, Italy
- Novartis Investigative Site — Oslo, Norway
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Seoul, Korea, South Korea
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — A Coruña, Galicia, Spain
- Novartis Investigative Site — Las Palmas de Gran Canarias, Las Palmas de Gran Canaria, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Taipei, Taiwan ROC, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.